Cel AI Valuation
Is CLAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CLAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CLAI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CLAI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLAI?
Key metric: As CLAI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CLAI's PS Ratio? | |
|---|---|
| PS Ratio | 5.8x |
| Sales | UK£54.16k |
| Market Cap | UK£316.18k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CLAI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5x | ||
VOY Mendell Helium | 4.3x | n/a | UK£1.3m |
BAR Brand Architekts Group | 0.5x | n/a | UK£7.8m |
PXS Provexis | 14.8x | n/a | UK£11.8m |
CRL Creightons | 0.4x | n/a | UK£23.3m |
CLAI Cel AI | 5.8x | n/a | UK£316.2k |
Price-To-Sales vs Peers: CLAI is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (5x).
Price to Sales Ratio vs Industry
How does CLAI's PS Ratio compare vs other companies in the European Personal Products Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: CLAI is expensive based on its Price-To-Sales Ratio (5.8x) compared to the European Personal Products industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is CLAI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CLAI's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ontex Group
€620.0m
Develops, produces, and supplies personal hygiene products and solutions for baby, feminine, and adult care in Belgium, the United Kingdom, the United States, Italy, France, and internationally.
0QVQ
€7.59
7D
2.4%
1Y
7.7%
McBride
UK£182.8m
Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.
MCBL
UK£1.05
7D
3.5%
1Y
71.3%
Suominen Oyj
€174.5m
Manufactures and sells nonwovens as roll goods for wipes and other applications in Finland, the Americas, the rest of Europe, and internationally.
0M1M
€2.65
7D
0%
1Y
-47.8%